Bydureon BCise vs Byetta

exenatide extended-release (GLP-1 receptor agonist) vs exenatide (GLP-1 receptor agonist) — a complete side-by-side comparison.

AstraZenecaAstraZenecaSame active ingredient

Bydureon BCise weight loss

2.3%

Byetta weight loss

2.8%

Bydureon BCise dosing

Once weekly

Byetta dosing

Twice daily (within 60 min before meals)

Reviewed by Dr. Elena Vance, DOLast reviewed 4 sources cited

Quick Summary

Bydureon BCise (exenatide) and Byetta (exenatide) are both glp-1 receptor agonists. In clinical trials, Byetta showed greater weight loss (2.8% vs 2.3%).

See the comparison table below for detailed side-by-side data.

Bydureon BCise vs Byetta: Full Comparison

FeatureBydureon BCise(exenatide extended-release)Byetta(exenatide)
Active Ingredientexenatideexenatide
Drug ClassGLP-1 receptor agonistGLP-1 receptor agonist
ManufacturerAstraZenecaAstraZeneca
FDA Approved2012-01-272005-04-28
Approved Indications
  • Type 2 diabetes mellitus (adjunct to diet and exercise)
  • Type 2 diabetes mellitus (adjunct to diet and exercise)
Routesubcutaneous injectionsubcutaneous injection
FrequencyOnce weeklyTwice daily (within 60 min before meals)
Starting Dose2 mg weekly5 mcg twice daily
Maintenance Dose2 mg weekly10 mcg twice daily
Max Dose2 mg weekly10 mcg twice daily
Weight Loss (%)2.3%2.8%
A1C Reduction1.3%0.8%
Key TrialDURATION-1 (30 weeks)AC2993 Phase 3 (30 weeks)
List Price$800-$950/month$800-$900/month
With Insurance$25-$100/month (varies by plan)$25-$100/month (varies by plan)
Savings CardLimited savings programs availableLimited savings programs available

Side Effects: Bydureon BCise vs Byetta

Side EffectBydureon BCiseByetta
Nausea11%44%
Diarrhea9%13%
Injection site nodule10-17%Not reported
Headache8%9%
Vomiting4%13%
Constipation6%Not reported
Pancreatitis (rare)<1%<1%
DizzinessNot reported9%
DyspepsiaNot reported6%
Jittery feelingNot reported4%

Severity scale: 1 (mild) to 5 (serious). Based on FDA prescribing information and clinical trial data.

Related Comparisons

Frequently Asked Questions

Sources & References

  1. Bydureon BCise FDA prescribing information
  2. Byetta FDA prescribing information
  3. Drucker DJ et al., Lancet 2008;372:1240-1250. FDA prescribing information.
  4. DeFronzo RA et al., Diabetes Care 2005;28:1092-1100.

This content is for informational purposes only and is not medical advice. Always consult your healthcare provider before making medication decisions. See our full medical disclaimer.